Moderna
MRNA
$0.00 (0.00%)
1D
1W
3M
1Y
5Y
ALL
Moderna, Inc. is a biotechnology company that is focused on creating a transformative medicines based on messenger ribonucleic acid (mRNA), to improve the lives of patients. The Company’s mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane, or secreted proteins that have a therapeutic or preventive benefit with the potential to address a range of spectrum of diseases. It is developing vaccines and therapeutics for infectious diseases, immuno-oncology, rare diseases, autoimmune and cardiovascular diseases, independently and with its strategic collaborators. The Company develops technologies that enable the development of mRNA medicines for diverse applications. It has created modalities, including prophylactic vaccines, systemic secreted and cell surface therapeutics, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, and systemic intracellular therapeutics.
Open
Prior close
Today's high
Today's low
52 Week high
52 Week low
Seeking Alpha • 3 days ago • MRNA
Moderna Vs. Novavax: 2 Pandemic Vaccine Pioneers - Which Offers Better Value Today?
Reuters • 3 days ago • MRNA
Moderna CMO Jacqueline Miller to step down
Accesswire • 3 days ago • MRNA
Dr. David Berman to Join Moderna as Chief Development Officer
GlobeNewsWire • 3 days ago • MRNA
RECORDATI ANNOUNCES STRATEGIC COLLABORATION WITH MODERNA TO DEVELOP AND COMMERCIALIZE WORLDWIDE mRNA 3927 FOR THE TREATMENT OF PROPIONIC ACIDEMIA
The Motley Fool • 4 days ago • MRNA
This Stock Is Already Up 58% This Year. Is It a Buy?
Charts and pricing are provided for informational purposes only. The current market data is delayed up to 15 minutes. The accuracy of any market data displayed is not guaranteed.